Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Camrelizumab + Dalpiciclib in advanced CRC, NSCLC, and HCC
NCT03601598Phase 2Unknown
- Sponsor
- Harbin Medical University
- Start
- Jul 2018
- Primary completion
- Jul 2019
- Modality
- Small Molecules, Immune Checkpoint Inhibitors
01
Overview
A Phase 2 trial of camrelizumab, dalpiciclib in colorectal cancer (CRC), non-small cell lung cancer (NSCLC), hepatocellular carcinoma (HCC), sponsored by Harbin Medical University. Status: unknown.
02
Drugs
camrelizumabdalpiciclib
03
Conditions
colorectal cancer (CRC)non-small cell lung cancer (NSCLC)hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT03601598.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03601598.